Eli Lilly Shares Fall 1.55% After Novo Nordisk Cuts GLP-1 Prices 50%
Novo Nordisk will cut U.S. GLP-1 list prices by up to 50%, lowering Wegovy, Ozempic and Rybelsus to $675 monthly and triggering a 1.55% drop in Eli Lilly shares to $1,042.15. Lilly’s 20%+ EPS growth may mitigate pressure as its CagriSema weight-loss drug underperformed.
1. Novo Nordisk Announces 50% Price Reductions
Novo Nordisk will implement up to 50% U.S. list price cuts on Wegovy, Ozempic and Rybelsus starting in 2027, reducing monthly prices from the current $1,027–$1,350 range to $675. This aims to lower out-of-pocket costs for patients in high-deductible and coinsurance plans.
2. Impact on Eli Lilly Share Price
Eli Lilly shares fell 1.55% to $1,042.15 on February 24 after the announcement, as investors anticipate intensified pricing competition in the GLP-1 market and potential margin pressure on Lilly’s diabetes and obesity portfolio.
3. Lilly’s Financial Resilience
Lilly has delivered over 20% EPS growth and maintains a strong balance sheet, factors that could help absorb margin compression and support ongoing investment in R&D and commercialization initiatives.
4. Pipeline Challenges with CagriSema
Recent trial results showed Lilly’s next-generation weight-loss candidate CagriSema underperformed key endpoints, raising concerns about its ability to counter discounted rival therapies and sustain long-term market share.